Association between arsenic suppression of adipogenesis and induction of CHOP10 via the endoplasmic reticulum stress response

Environmental Health Perspectives

Volumn 121, Issue 2, 2013, Pages 237-243

  Hou, Yongyong ^a   Xue, Peng ^a   Woods, Courtney G ^a   Wang, Xia ^a,b   Fu, Jingqi ^a   Yarborough, Kathy ^a   Qu, Weidong ^b   Zhang, Qiang ^a   Andersen, Melvin E ^a   Pi, Jingbo ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

Adipogenesis; Arsenic; C EBP; CHOP10; Preadipocytes; Type 2 diabetes

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ARSENIC; ARSENIC TRIOXIDE; BREFELDIN A; CCAAT ENHANCER BINDING PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INITIATION FACTOR 2ALPHA; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THAPSIGARGIN; TUNICAMYCIN; X BOX BINDING PROTEIN 1;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL FRACTIONATION; CELL STRAIN 3T3; CONTROLLED STUDY; CYTOTOXICITY; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; INSULIN RESISTANCE; MOUSE; NONHUMAN; NOTE; PRIORITY JOURNAL; PROADIPOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

3T3-L1 CELLS; ADIPOGENESIS; ANIMALS; ARSENIC; BLOTTING, WESTERN; ENDOPLASMIC RETICULUM; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTOR CHOP;

EID: 84873387695     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1205731     Document Type: Note

References (41)

1. Andra SS, Makris KC, Christophi CA, Ettinger AS. 2013. Delineating the degree of association between biomarkers of arsenic exposure and type-2 diabetes mellitus. Int J Hyg Environ Health 216(1):35-49.
2. Banhegyi G, Baumeister P, Benedetti A, Dong D, Fu Y, Lee AS, et al. 2007. Endoplasmic reticulum stress. Ann NY Acad Sci 1113:58-71.
3. Batchvarova N, Wang XZ, Ron D. 1995. Inhibition of adipogenesis by the stress-induced protein CHOP (Gadd153). EMBO J 14(19):4654-4661.
4. Cannon B, Nedergaard J. 2001. Cultures of adipose precursor cells from brown adipose tissue and of clonal brown-adipocyte-like cell lines. Methods Mol Biol 155:213-224.
5. Clarke SL, Robinson CE, Gimble JM. 1997. CAAT/enhancer binding proteins directly modulate transcription from the peroxisome proliferator-activated receptor g2 promoter. Biochem Biophys Res Commun 240(1):99-103.
6. Cnop M, Foufelle F, Velloso LA. 2011. Endoplasmic reticulum stress, obesity and diabetes. Trends Mol Med 18(1):59-68.
7. Coronado-González JA, Del Razo LM, García-Vargas G, Sanmiguel-Salazar F, Escobedo-de la Pena J. 2007. Inorganic arsenic exposure and type 2 diabetes mellitus in Mexico. Environ Res 104(3):383-389.
8. Cullen WR, McBride BC, Manji H, Pickett AW, Reglinski J. 1989. The metabolism of methyl arsine oxide and sulfide. Appl Organomet Chem 3:71-78.
9. Darlington GJ, Ross SE, MacDougald OA. 1998. The role of C/EBP genes in adipocyte differentiation. J Biol Chem 273(46):30057-30060.
10. Garg A, Agarwal AK. 2009. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta 1791(6):507-513.
11. Hill DS, Wlodarczyk BJ, Mitchell LE, Finnell RH. 2009. Arsenate-induced maternal glucose intolerance and neural tube defects in a mouse model. Toxicol Appl Pharmacol 239(1):29-36.
12. Hou Y, Xue P, Bai Y, Liu D, Woods CG, Yarborough K, et al. 2012. Nuclear factor erythroid-derived factor 2-related factor 2 regulates transcription of CCAAT/enhancer- binding protein b during adipogenesis. Free Radic Biol Med 52(2):462-472.
13. Islam R, Khan I, Hassan SN, McEvoy M, D'Este C, Attia J, et al. 2012. Association between type 2 diabetes and chronic arsenic exposure in drinking water: a cross sectional study in Bangladesh. Environ Health 11:38; doi:10.1186/1476-069X-11-38 [Online 7 June 2012].
14. Izquierdo-Vega JA, Soto CA, Sanchez-Peña LC, De Vizcaya-Ruiz A, Del Razo LM. 2006. Diabetogenic effects and pancreatic oxidative damage in rats sub chronically exposed to arsenite. Toxicol Lett 160(2):135-142.
15. Lowell BB, Shulman GI. 2005. Mitochondrial dysfunction and type 2 diabetes. Science 307(5708):384-387.
16. Maull EA, Ahsan H, Edwards J, Longnecker MP, Navas-Acien A, Pi J, et al. 2012. Evaluation of the association between arsenic and diabetes: a National Toxicology Program workshop review. Environ Health Perspect 120:1658-1670.
17. III)-induced cytotoxicity. Toxicol Appl Pharmacol 260(3):241-249.
18. Oh RS, Pan WC, Yalcin A, Zhang H, Guilarte TR, Hotamisligil GS, et al. 2012. Functional RNA interference (RNAi) screen identi-fes system A neutral amino acid transporter 2 (SNAT2) as a mediator of arsenic-induced endoplasmic reticulum stress. J Biol Chem 287(8):6025-6034.
19. Oyadomari S, Mori M. 2004. Roles of CHOP/GADD153 in endo-plasmic reticulum stress. Cell Death Differ 11(4):381-389.
20. Paul DS, Harmon AW, Devesa V, Thomas DJ, Styblo M. 2007. Molecular mechanisms of the diabetogenic effects of arsenic: inhibition of insulin signaling by arsenite and methyl-arsonous acid. Environ Health Perspect 115:734-742.
21. Paul DS, Walton FS, Saunders RJ, Styblo M. 2011. Characterization of the impaired glucose homeostasis produced in C57BL/6 mice by chronic exposure to arsenic and high-fat diet. Environ Health Perspect 119:1104-1109.
22. III) and arsenite: LD50 in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol 14(6):651-656.
23. Pi J, Yamauchi H, Kumagai Y, Sun G, Yoshida T, Aikawa H, et al. 2002. Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ Health Perspect 110:331-336.
24. Ron D, Habener JF. 1992. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant- negative inhibitor of gene transcription. Genes Dev 6(3):439-453.
25. Rosen ED, MacDougald OA. 2006. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 7(12):885-896.
26. Rosen ED, Spiegelman BM. 2006. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444(7121):847-853.
27. Su CT, Lin HC, Choy CS, Huang YK, Huang SR, Hsueh YM. 2012. The relationship between obesity, insulin and arsenic methyl action capability in Taiwan adolescents. Sci Total Environ 414:152-158.
28. Tang QQ, Lane MD. 2000. Role of C/EBP homologous protein (CHOP-10) in the programmed activation of CCAAT/ enhancer- binding protein-b during adipogenesis. Proc Natl Acad Sci USA 97(23):12446-12450.
29. Tontonoz P, Spiegelman BM. 2008. Fat and beyond: the diverse biology of PPARg. Annu Rev Biochem 77:289-312.
30. Trouba KJ, Wauson EM, Vorce RL. 2000. Sodium arsenite inhibits terminal differentiation of murine C3H 10T1/2 preadipocytes. Toxicol Appl Pharmacol 168(1):25-35.
31. Tseng CH. 2004. The potential biological mechanisms of arsenic- induced diabetes mellitus. Toxicol Appl Pharmacol 197(2):67-83.
32. Tseng CH, Tai TY, Chong CK, Tseng CP, Lai MS, Lin BJ, et al. 2000. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect 108:847-851.
33. Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D. 2001. Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol 172(3):225-232.
34. Vigouroux C, Caron-Debarle M, Le Dour C, Magre J, Capeau J. 2011. Molecular mechanisms of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and lipotoxicity. Int J Biochem Cell Biol 43(6):862-876.
35. Walton FS, Harmon AW, Paul DS, Drobna Z, Patel YM, Styblo M. 2004. Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: possible mechanism of arsenic-induced diabetes. Toxicol Appl Pharmacol 198(3):424-433.
36. Wang ZX, Jiang CS, Liu L, Wang XH, Jin HJ, Wu Q, et al. 2005. The role of Akt on arsenic trioxide suppression of 3T3-L1 preadipocyte differentiation. Cell Res 15(5):379-386.
37. Watanabe C, Matsui T, Inaoka T, Kadono T, Miyazaki K, Bae MJ, et al. 2007. Dermatological and nutritional/growth effects among children living in arsenic-contaminated communities in rural Bangladesh. J Environ Sci Health A Tox Hazard Subst Environ Eng 42(12):1835-1841.
38. Wauson EM, Langan AS, Vorce RL. 2002. Sodium arsenite inhibits and reverses expression of adipogenic and fat cell-specific genes during in vitro adipogenesis. Toxicol Sci 65(2):211-219.
39. Xue P, Hou Y, Chen Y, Yang B, Fu J, Zheng H, et al. 2012. Adipose deficiency of Nrf2 in ob/ob mice results in severe metabolic syndrome. Diabetes; doi:10.2337/db12-0584 [Online 13 December 2012].
40. Xue P, Hou Y, Zhang Q, Woods CG, Yarborough K, Liu H, et al. 2011. Prolonged inorganic arsenite exposure suppresses insulin-stimulated AKT S473 phosphorylation and glucose uptake in 3T3-L1 adipocytes: involvement of the adaptive antioxidant response. Biochem Biophys Res Commun 407(2):360-365.
41. Yu J, Kwon KB, Park JW, Chae HJ, Park BH. 2009. Bax inhibitor-1 over expression reduces the suppressive effect of calcium mobilizing agent on adipogenesis. Int J Biochem Cell Biol 41(8-9):1739-1745.